Gabriel Ivey

[Gabriel Ivey @GDIveyMD]

(2/2) None of this is possible, however, without the trust that our patients and their families have given us. They are why we fight. Thank you, MK, for sharing your story. #FightCancer

https://t.co/A7AMlCpiAE

[Gabriel Ivey @GDIveyMD]

(1/2) There truly are no words to express how grateful I am to have been given this opportunity. It has been a tremendous privilege and honor serving in the National Capital Region. I am so very proud of the team we have assembled. I am not alive without them.

[Surgical Oncology Insight @SurgOncInsight]

Sept Issue: The impact of a #BloodlessMedicine program on #PancreaticResections : A single-institution experience incorporating patients with borderline-resectable and locally advanced #PancreaticCancer @GDIveyMD @wrburnsmd

https://t.co/xlv6yuf4ih

@FlavioRochaMD
@SKMaithel

[Gabriel Ivey @GDIveyMD]

Thanks again for the opportunity @HUMAADoctors! It’s always great being back at HUCM! @HowardU

[Gabriel Ivey @GDIveyMD]

@YewandeAlimiMD @SocietyofBAS Thank you @YewandeAlimiMD! I appreciate you!

[Gabriel Ivey @GDIveyMD]

@saejoco Thank you, Dr. Conway!

[Gabriel Ivey @GDIveyMD]

@KeithKow @GUH_WHCSurgRes @wbalrefaie @p_g_j_ Thank you, Dr. Kowalczyk!

[Gabriel Ivey @GDIveyMD]

@p_g_j_ @GUH_WHCSurgRes @wbalrefaie @YewandeAlimiMD @drdavidsong Thank you, Dr. Jackson!

[Gabriel Ivey @GDIveyMD]

@TrankiemTrauma @GUH_WHCSurgRes Thank you, Dr. Trankiem!

[Gabriel Ivey @GDIveyMD]

Thank you @hopkinssurgery! Tremendously honored to be on the team!

[Hopkins Surgery @hopkinssurgery]

Johns Hopkins Adds Surgical Oncology to National Capital Region and Welcomes Surgical Oncologist Dr. Gabriel Ivey.

https://t.co/Pf2roCnj6A

[Gabriel Ivey @GDIveyMD]

@HenriFordMD @umiamimedicine Congrats, Dr. Ford!!!

[Gabriel Ivey @GDIveyMD]

Thank you @AshRajputInDC! Excited to be on the team!

[Ashwani Rajput @AshRajputInDC]

A very warm welcome to my colleague, Dr. Gabriel Ivey. He joins the Johns Hopkins Surgical Oncology team in the DC region. @hopkinskimmel @hopkinssurgery @sibleyonline @SuburbanHosp @HopkinsMedicine

[Clinical Cancer Research @CCR_AACR]

#MetastaticMelanoma patients who underwent treatment with TIL ACT showed decreased responses in patients previously treated with anti PD-1 agents. Levi et al explore the reasons for this response
https://t.co/iJAkUsNoUP
@shirleynah @GDIveyMD @franklowery @slgoff_SB